Expanding the Options for Risk-based Therapy in Febrile Neutropenia
- 1 June 1998
- journal article
- review article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 31 (2) , 411-416
- https://doi.org/10.1016/s0732-8893(98)00034-0
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained FeverClinical Infectious Diseases, 1997
- Outcomes of Bacteremia in Patients with Cancer and Neutropenia: Observations from Two Decades of Epidemiological and Clinical TrialsClinical Infectious Diseases, 1997
- Imipenem/CilastatinDrugs, 1996
- Safety profile of meropenem: International clinical experience based on the first 3125 patients treated with meropenemJournal of Antimicrobial Chemotherapy, 1995
- Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trialThe American Journal of Medicine, 1995
- Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem.Journal of Clinical Oncology, 1995
- The Changing Epidemiology of Infections at Cancer HospitalsClinical Infectious Diseases, 1993
- Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancerCancer, 1993
- A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patientsArchives of internal medicine (1960), 1992
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966